Vertical Entertainment has just acquired the U.S. rights for the highly anticipated sci-fi horror thriller, The Cure. The film will land in theaters and on demand in 2026, according to Deadline.
The film stars Samantha Cochran (V/H/S/Halloween), horror veteran David Dastmalchian (Late Night with the Devil), and Ashley Greene (Twilight). The supporting cast includes Sydney Taylor (American Born Chinese), Tyler Lawrence Gray (Wolfpack), and Dylan Flashner (The Card Counter).
The Cure plunges into a chilling narrative centered on Ally Braun (Cochran). She is a 16-year-old adoptee battling a puzzling, debilitating illness. Her life takes a sinister turn when she uncovers the horrifying truth. Her adoptive parents (Dastmalchian and Greene), biotech billionaires, are secretly harvesting her blood for their own nefarious purposes. The film explores themes of ethical boundaries, familial betrayal, and the terrifying potential of unchecked corporate science.
Nancy Leopardi directs the feature from a script penned by the writing duo Jonathan Bernstein and James Greer (Unsane).
Director Nancy Leopardi, who also produces alongside Bo Youngblood, John Ierardi, and Natalie Marciano, views the film as more than just a horror flick. She describes The Cure as “a satirical take on the modern billionaire class cloaked in a crowd-pleasing thriller.”
Leopardi elaborated on the film’s conceptual foundation, noting its connection to classic, thought-provoking genre cinema:
“The Cure is made in the tradition of classic horror and sci-fi films that are inspired by terrifying socio-political realities and advances in bio-technology,” said Leopardi. “Like Ex Machina, A.I., and Videodrome, I believe we are on the cusp of a revolution in science and the big question is – who will benefit?”
The Cure promises a terrifying blend of body horror, sci-fi concepts, and timely social commentary about the powerful elite.
